Evidence map›Paper›PMID 36982541›Full record

ArticleInternational journal of molecular sciences2023

Microarrays, Enzymatic Assays, and MALDI-MS for Determining Specific Alterations to Mitochondrial Electron Transport Chain Activity, ROS Formation, and Lipid Composition in a Monkey Model of Parkinson's Disease.

María Dolores García-Fernández, Ane Larrea, Roberto Fernández, Rafael Rodríguez-Puertas, Egoitz Astigarraga, Iván Manuel, Gabriel Barreda-Gómez

Open access · goldFull text read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

María Dolores García-FernándezResearch and Development Department, IMG Pharma Biotech S.L., 48160 Derio, Spain.
Ane LarreaResearch and Development Department, IMG Pharma Biotech S.L., 48160 Derio, Spain.
Roberto FernándezResearch and Development Department, IMG Pharma Biotech S.L., 48160 Derio, Spain.ORCID 0000-0002-3424-9758
Rafael Rodríguez-PuertasDepartment of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country, UPV/EHU, 48940 Leioa, Spain.ORCID 0000-0003-4517-5114
Egoitz AstigarragaResearch and Development Department, IMG Pharma Biotech S.L., 48160 Derio, Spain.ORCID 0000-0002-0338-5554
Iván ManuelDepartment of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country, UPV/EHU, 48940 Leioa, Spain.
Gabriel Barreda-GómezResearch and Development Department, IMG Pharma Biotech S.L., 48160 Derio, Spain.ORCID 0000-0002-8330-1567
University of the Basque Country · ES

Funding

Basque Government IT1454-22ISCIII Spanish Monistry for Health and co-founded by the European Union PI20/00153Ministry of Economy and Competitiveness IPT-2011-1205Scholarship Program for the Transition fron Educational to Occupational Word (UPV-Basque Government)
6 · The paper itself

Abstract

Multiple evidences suggest that mitochondrial dysfunction is implicated in the pathogenesis of Parkinson's disease via the selective cell death of dopaminergic neurons, such as that which occurs after prolonged exposure to the mitochondrial electron transport chain (ETC) complex I inhibitor, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrine (MPTP). However, the effects of chronic MPTP on the ETC complexes and on enzymes of lipid metabolism have not yet been thoroughly determined. To face these questions, the enzymatic activities of ETC complexes and the lipidomic profile of MPTP-treated non-human primate samples were determined using cell membrane microarrays from different brain areas and tissues. MPTP treatment induced an increase in complex II activity in the olfactory bulb, putamen, caudate, and

Indexed as

Parkinson Disease1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsElectron TransportEnzyme AssaysHaplorhiniLipidsMiceMice, Inbred C57BLReactive Oxygen SpeciesSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationSubstantia Nigra1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineLipidsReactive Oxygen SpeciesMALDI imaging mass spectrometrymicroarraymitochondriaParkinson’s disease

Identifiers

PMID36982541
PMCPMC10049643
OpenAlexW4324057253

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read28
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.